Skip to content
Disclosery

ARCH Venture Management, LLC

Follow

13F filer, CIK 1274403, CHICAGO, IL

ARCH Venture Management, LLC reported $651,681,142 across 9 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-26-000153

Period
2025-12-31
Reported value
$652M
Holdings
9
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TXGnew+737,539$12M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CEROexited-22,389-$114K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001012975-26-000153, largest first. % of portfolio is the value over $651,681,142, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,120,053 shares; 2025Q2: 4,120,053 shares; 2025Q3: 4,120,053 shares; 2025Q4: 4,120,053 shares 4,120,053$171M26.19%0Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,834,653 shares; 2024Q4: 4,540,132 shares; 2025Q1: 4,540,132 shares; 2025Q2: 4,540,132 shares; 2025Q3: 4,540,132 shares; 2025Q4: 4,540,132 shares 4,540,132$126M19.31%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,728,738 shares; 2024Q4: 3,728,738 shares; 2025Q1: 3,728,738 shares; 2025Q2: 3,728,738 shares; 2025Q3: 3,728,738 shares; 2025Q4: 3,728,738 shares 3,728,738$113M17.36%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,820,634 shares; 2025Q3: 2,759,072 shares; 2025Q4: 2,759,072 shares 2,759,072$84.9M13.03%0Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 12,916,663 shares; 2025Q3: 12,916,663 shares; 2025Q4: 12,916,663 shares 12,916,663$77.9M11.95%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,055,554 shares; 2024Q4: 11,055,554 shares; 2025Q1: 11,055,554 shares; 2025Q2: 11,055,554 shares; 2025Q3: 11,055,554 shares; 2025Q4: 11,055,554 shares 11,055,554$41.1M6.31%0Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,055,916 shares; 2024Q4: 8,055,916 shares; 2025Q1: 8,055,916 shares; 2025Q2: 8,055,916 shares; 2025Q3: 8,055,916 shares; 2025Q4: 8,055,916 shares 8,055,916$25M3.83%0Timeline
TXG10X GENOMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 737,539 shares 737,539$12M1.85%newTimeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 320,482 shares; 2024Q4: 320,482 shares; 2025Q1: 320,482 shares; 2025Q2: 320,482 shares; 2025Q3: 320,482 shares; 2025Q4: 320,482 shares 320,482$1.06M0.16%0Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CEROCERO THERAPEUTICS HLDGS INC22,389$114Kshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-26-000153 base2026-02-17acceptance time not in the bulk data set